198 related articles for article (PubMed ID: 28482402)
1. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
Li Z; Chen ZW; Ren H; Hu P
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
[TBL] [Abstract][Full Text] [Related]
2. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
3. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
4. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus resistance to the new direct-acting antivirals.
Esposito I; Trinks J; Soriano V
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
[TBL] [Abstract][Full Text] [Related]
6. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
Premoli C; Aghemo A
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
[TBL] [Abstract][Full Text] [Related]
7. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
Welsch C
Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
[TBL] [Abstract][Full Text] [Related]
8. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
9. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.
Soria ME; Gregori J; Chen Q; García-Cehic D; Llorens M; de Ávila AI; Beach NM; Domingo E; Rodríguez-Frías F; Buti M; Esteban R; Esteban JI; Quer J; Perales C
BMC Infect Dis; 2018 Sep; 18(1):446. PubMed ID: 30176817
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
Ahmed A; Felmlee DJ
Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus: Viral Quasispecies and Genotypes.
Tsukiyama-Kohara K; Kohara M
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Wang Y; Rao HY; Xie XW; Wei L
Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
Molino S; Martin MT
Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
[TBL] [Abstract][Full Text] [Related]
14. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
Colpitts CC; Baumert TF
Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
16. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
19. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
20. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
Paolucci S; Premoli M; Novati S; Gulminetti R; Maserati R; Barbarini G; Sacchi P; Piralla A; Sassera D; De Marco L; Girello A; Mondelli MU; Baldanti F
Sci Rep; 2017 Nov; 7(1):16017. PubMed ID: 29167469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
